

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Systolic Blood Pressure (mmHg)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Screening/Day -4 to -1	43	127.3	128.0	9.16	110	150	39	-5.0	-4.0	9.85	-26	20
	Day 14	39	121.9	123.0	9.90	95	147						
Placebo	Screening/Day -4 to -1	43	125.6	128.0	11.79	96	150	42	-4.2	-4.0	12.56	-39	36
	Day 14	42	121.6	121.0	10.69	96	156						

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Temperature (C)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Screening/Day -4 to -1	43	37.0	37.0	0.49	36	38						
	Day 1	42	37.0	37.0	0.53	36	38	0
	Day 2	40	36.9	36.8	0.41	36	38	39	-0.2	-0.2	0.55	-2	1
	Day 3	41	36.7	36.7	0.33	36	38	41	-0.3	-0.2	0.48	-2	1
	Day 4	41	36.7	36.7	0.39	36	38	41	-0.3	-0.2	0.50	-1	1
	Day 5	41	36.6	36.7	0.55	36	39	41	-0.4	-0.3	0.63	-2	2
	Day 6	40	36.7	36.7	0.47	36	39	40	-0.4	-0.3	0.57	-1	1
	Day 7	41	36.7	36.7	0.35	36	38	41	-0.3	-0.2	0.52	-2	1
	Day 8	41	36.7	36.6	0.39	36	38	41	-0.4	-0.3	0.58	-2	1
	Day 9	40	36.7	36.7	0.31	36	38	40	-0.4	-0.3	0.58	-2	1
	Day 10	40	36.6	36.6	0.37	36	38	40	-0.4	-0.3	0.49	-2	1

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Temperature (C)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Day 11	40	36.6	36.5	0.53	35	38	40	-0.5	-0.6	0.71	-3	1
	Day 12	40	36.6	36.6	0.34	36	38	40	-0.4	-0.3	0.56	-2	1
	Day 13	41	36.5	36.7	0.77	32	38	41	-0.5	-0.4	0.98	-6	1
	Day 14	39	36.7	36.7	0.28	36	37	39	-0.3	-0.3	0.60	-2	1
	Day 15	36	36.6	36.6	0.27	36	38	36	-0.4	-0.3	0.52	-1	1
	Day 16	39	36.6	36.6	0.45	35	38	39	-0.4	-0.3	0.61	-2	1
	Day 17	39	36.6	36.6	0.39	36	38	39	-0.5	-0.4	0.55	-2	1
	Day 18	37	36.7	36.6	0.30	36	38	37	-0.3	-0.2	0.49	-2	1
	Day 19	39	36.6	36.6	0.34	36	38	39	-0.4	-0.3	0.45	-2	1
	Day 20	39	36.7	36.6	0.31	36	38	39	-0.4	-0.4	0.47	-2	1
	Day 21	37	36.7	36.7	0.25	36	38	37	-0.3	-0.2	0.52	-2	1
	Day 22	37	36.6	36.7	0.31	36	38	37	-0.3	-0.2	0.52	-2	1
	Day 23	37	36.7	36.7	0.27	36	38	37	-0.3	-0.2	0.53	-2	1
	Day 24	35	36.7	36.7	0.33	36	38	35	-0.3	-0.2	0.62	-2	2
	Day 25	36	36.6	36.6	0.30	36	37	36	-0.3	-0.2	0.60	-2	1

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Temperature (C)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Day 26	32	36.6	36.6	0.33	36	37	32	-0.4	-0.3	0.54	-2	0
	Day 27	35	36.7	36.7	0.34	36	38	35	-0.3	-0.2	0.61	-2	2
	Day 28	37	36.7	36.6	0.30	36	38	37	-0.3	-0.3	0.56	-2	1
Placebo	Screening/Day -4 to -1	43	37.2	37.1	0.60	36	39						
	Day 1	40	37.0	37.0	0.49	36	38	0
	Day 2	43	36.9	36.9	0.60	36	39	42	-0.1	-0.1	0.67	-2	2
	Day 3	43	36.9	36.8	0.86	34	39	43	-0.2	-0.2	0.74	-2	2
	Day 4	42	36.7	36.7	0.50	36	39	42	-0.3	-0.3	0.60	-2	1
	Day 5	42	36.7	36.8	0.43	36	38	42	-0.4	-0.3	0.54	-2	1
	Day 6	41	36.6	36.7	0.36	35	37	41	-0.4	-0.2	0.59	-2	0
	Day 7	42	36.6	36.7	0.44	35	37	42	-0.4	-0.3	0.62	-2	1
	Day 8	42	36.6	36.7	0.40	35	38	42	-0.4	-0.4	0.58	-2	1
	Day 9	41	36.6	36.7	0.38	35	37	41	-0.4	-0.3	0.55	-2	1
	Day 10	40	36.6	36.6	0.44	35	38	40	-0.4	-0.3	0.58	-2	1
	Day 11	40	36.6	36.6	0.44	35	37	40	-0.4	-0.3	0.64	-2	1

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Temperature (C)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Placebo	Day 12	40	36.6	36.7	0.38	35	37	40	-0.4	-0.3	0.58	-2	1
	Day 13	40	36.6	36.6	0.41	35	37	40	-0.4	-0.3	0.60	-2	1
	Day 14	42	36.6	36.6	0.32	36	38	42	-0.4	-0.4	0.63	-2	1
	Day 15	39	36.6	36.7	0.40	35	37	39	-0.5	-0.4	0.64	-2	1
	Day 16	42	36.7	36.6	0.44	35	38	42	-0.4	-0.3	0.62	-2	1
	Day 17	40	36.6	36.7	0.39	35	37	40	-0.4	-0.2	0.59	-2	1
	Day 18	39	36.7	36.7	0.35	36	37	39	-0.3	-0.3	0.54	-2	1
	Day 19	39	36.5	36.6	0.41	35	37	39	-0.5	-0.4	0.63	-2	1
	Day 20	37	36.7	36.7	0.36	35	37	37	-0.4	-0.2	0.63	-2	1
	Day 21	37	36.6	36.6	0.46	35	37	37	-0.4	-0.2	0.63	-2	1
	Day 22	36	36.6	36.7	0.39	36	37	36	-0.4	-0.2	0.67	-2	1
	Day 23	39	36.7	36.7	0.42	35	37	39	-0.3	-0.3	0.66	-2	1
	Day 24	38	36.7	36.7	0.31	36	37	38	-0.4	-0.3	0.64	-2	1
	Day 25	35	36.7	36.7	0.36	36	37	35	-0.3	-0.2	0.60	-2	1
	Day 26	37	36.6	36.7	0.41	35	37	37	-0.4	-0.4	0.65	-2	1

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter:Temperature (C)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Placebo	Day 27	37	36.6	36.6	0.37	36	37	37	-0.4	-0.3	0.65	-2	1
	Day 28	38	36.6	36.6	0.47	35	37	38	-0.5	-0.4	0.68	-2	1

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter:Heart Rate (beats/min)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Screening/Day -4 to -1	43	79.0	79.0	8.38	64	100						
	Day 14	39	74.6	75.0	7.42	60	86	39	-3.9	-4.0	9.30	-22	19
Placebo	Screening/Day -4 to -1	43	84.3	82.0	13.17	59	119						
	Day 14	42	75.4	74.0	7.01	61	92	42	-9.3	-10.0	13.30	-54	19

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Diastolic Blood Pressure (mmHg)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Screening/Day -4 to -1	43	79.4	80.0	7.81	60	96						
	Day 14	39	76.8	79.0	7.29	60	98	39	-2.2	-2.0	6.69	-19	14
Placebo	Screening/Day -4 to -1	43	78.9	80.0	8.07	58	92						
	Day 14	42	75.1	76.0	6.74	60	88	42	-3.7	-3.5	8.26	-24	15

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter:Respiratory Rate (breaths/min)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Screening/Day -4 to -1	43	18.4	18.0	1.79	16	23						
	Day 1	42	18.8	18.5	1.86	16	23	0
	Day 2	37	18.1	18.0	2.30	12	24	36	-0.8	-1.0	2.54	-6	8
	Day 3	38	17.7	18.0	2.18	10	20	38	-1.2	-1.0	2.60	-10	4
	Day 4	38	17.3	18.0	1.96	12	20	38	-1.5	-2.0	2.53	-8	4

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter:Respiratory Rate (breaths/min)

Treatment	Visit	Observed						Change from baseline					
		n	Mean	Median	SD	Min	Max	n	Mean	Median	SD	Min	Max
Tafenoquine	Day 5	39	17.3	18.0	2.07	12	22	39	-1.6	-1.0	2.53	-8	4
	Day 6	39	17.2	18.0	2.47	10	23	39	-1.6	-2.0	3.00	-10	7
	Day 7	39	17.8	18.0	3.86	10	36	39	-1.0	-2.0	4.10	-10	16
	Day 8	38	17.0	17.0	2.42	10	21	38	-1.8	-2.0	2.88	-10	3
	Day 9	39	17.1	17.0	3.16	9	28	39	-1.7	-2.0	3.34	-8	8
	Day 10	39	17.1	17.0	2.84	12	28	39	-1.7	-2.0	3.15	-8	8
	Day 11	38	16.7	17.0	2.45	11	24	38	-2.2	-2.0	3.00	-8	4
	Day 12	38	16.8	17.0	2.33	10	21	38	-2.0	-1.0	3.19	-10	4
	Day 13	39	16.8	17.0	2.42	11	24	39	-2.0	-2.0	3.03	-9	4
	Day 14	39	16.8	16.0	1.73	14	20	39	-1.9	-2.0	2.63	-7	3
	Day 15	35	16.3	16.0	2.38	10	22	35	-2.4	-2.0	3.20	-10	3
	Day 16	38	16.3	16.0	2.20	11	20	38	-2.5	-2.0	2.99	-9	3
	Day 17	38	16.4	16.5	2.00	11	20	38	-2.4	-2.0	3.12	-9	4
	Day 18	37	16.4	16.0	2.14	11	21	37	-2.5	-2.0	3.12	-9	4
	Day 19	38	16.6	16.5	2.05	11	21	38	-2.2	-2.0	2.74	-9	3

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter:Respiratory Rate (breaths/min)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Day 20	38	16.6	16.5	2.22	12	21	38	-2.2	-2.0	3.15	-8	4
	Day 21	36	16.5	16.0	2.48	9	21	36	-2.3	-2.0	2.90	-7	2
	Day 22	35	16.6	16.0	1.80	12	21	35	-2.1	-2.0	2.60	-7	3
	Day 23	35	16.5	16.0	2.17	12	21	35	-2.4	-2.0	3.00	-7	3
	Day 24	33	16.3	16.0	1.91	12	20	33	-2.4	-2.0	2.77	-7	2
	Day 25	35	16.6	16.0	2.14	12	21	35	-2.1	-2.0	2.94	-7	4
	Day 26	32	16.5	16.0	2.16	12	21	32	-2.3	-2.5	3.07	-7	3
	Day 27	35	16.5	16.0	2.12	12	21	35	-2.3	-2.0	3.05	-8	4
Placebo	Day 28	36	16.4	16.0	1.96	12	20	36	-2.4	-2.5	3.03	-8	4
	Screening/Day -4 to -1	43	18.8	19.0	2.16	13	24						
	Day 1	40	19.0	19.0	2.01	15	23	0
	Day 2	39	20.9	19.0	12.49	14	94	39	2.0	-1.0	12.60	-4	76
	Day 3	36	18.4	18.0	3.07	13	32	36	-0.5	-1.0	3.43	-6	14
	Day 4	36	20.8	18.0	13.78	15	99	36	1.8	-1.0	13.99	-6	81
	Day 5	38	18.0	18.0	2.56	11	24	38	-0.9	-1.0	3.11	-9	7

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter:Respiratory Rate (breaths/min)

Treatment	Visit	Observed						Change from baseline					
		n	Mean	Median	SD	Min	Max	n	Mean	Median	SD	Min	Max
Placebo	Day 6	38	18.0	18.0	2.70	11	24	38	-1.0	-2.0	2.75	-6	6
	Day 7	39	18.1	18.0	2.74	11	26	39	-0.8	-1.0	3.22	-6	7
	Day 8	39	17.7	17.0	2.82	12	26	39	-1.2	-2.0	3.27	-6	6
	Day 9	39	17.9	18.0	2.79	11	24	39	-1.0	-1.0	3.32	-7	7
	Day 10	38	17.3	17.0	2.98	11	28	38	-1.5	-2.0	3.67	-7	10
	Day 11	38	17.7	17.0	3.15	12	28	38	-1.2	-1.0	3.86	-7	10
	Day 12	38	17.4	17.0	2.95	11	28	38	-1.4	-2.0	3.69	-7	10
	Day 13	39	17.6	17.0	3.14	11	28	39	-1.2	-1.0	3.82	-7	10
	Day 14	42	16.8	16.5	1.77	14	20	42	-2.1	-2.0	2.93	-7	5
	Day 15	36	17.5	16.5	3.14	11	28	36	-1.4	-2.0	3.82	-7	10
	Day 16	40	17.9	17.0	3.64	12	32	40	-1.0	-1.0	4.29	-8	14
	Day 17	39	17.7	17.0	3.71	12	32	39	-1.1	-1.0	4.44	-7	14
	Day 18	37	17.5	17.0	3.31	11	28	37	-1.5	-2.0	3.98	-8	10
	Day 19	37	17.5	17.0	3.26	12	28	37	-1.5	-2.0	4.04	-8	10
	Day 20	36	17.7	18.0	3.14	12	28	36	-1.3	-2.0	3.79	-7	10

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter:Respiratory Rate (breaths/min)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Placebo	Day 21	36	17.5	17.0	3.23	12	28	36	-1.3	-1.5	3.79	-7	10
	Day 22	35	17.7	17.0	3.25	11	28	35	-1.1	-1.0	3.73	-6	10
	Day 23	39	17.6	17.0	2.73	11	24	39	-1.2	-2.0	3.33	-6	7
	Day 24	37	17.5	17.0	3.27	12	28	37	-1.5	-2.0	3.75	-7	10
	Day 25	34	17.7	17.5	3.48	12	32	34	-1.1	-1.0	4.14	-7	14
	Day 26	36	17.8	17.0	3.54	12	32	36	-1.0	-0.5	4.19	-7	14
	Day 27	36	17.7	17.0	3.44	12	32	36	-1.2	-1.0	4.15	-7	14
	Day 28	38	17.5	17.0	3.26	12	32	38	-1.3	0.0	4.06	-7	14

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Oxygen Saturation (%)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Screening/Day -4 to -1	43	97.3	97.0	1.31	94	100						
	Day 1	42	97.0	97.0	1.41	94	99	0
	Day 2	41	96.5	97.0	1.87	91	99	40	-0.7	0.0	1.87	-6	2
	Day 3	41	96.8	97.0	1.86	91	99	41	-0.4	0.0	1.50	-4	3
	Day 4	41	97.0	98.0	1.79	92	99	41	-0.1	0.0	1.73	-6	3
	Day 5	40	96.8	97.5	1.96	91	99	40	-0.3	0.0	1.68	-6	2
	Day 6	41	96.5	97.0	2.39	88	99	41	-0.6	0.0	2.13	-7	3

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Oxygen Saturation (%)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Day 7	41	96.7	98.0	2.36	88	99	41	-0.5	0.0	2.18	-7	2
	Day 8	41	96.7	98.0	2.26	87	100	41	-0.4	0.0	1.99	-7	2
	Day 9	41	97.0	98.0	1.88	90	100	41	-0.2	0.0	1.62	-4	2
	Day 10	41	96.8	97.0	1.79	92	100	41	-0.3	0.0	1.74	-6	3
	Day 11	40	97.0	98.0	2.12	87	99	40	-0.2	0.0	1.84	-8	2
	Day 12	40	97.1	98.0	1.93	91	100	40	-0.2	1.0	1.99	-6	3
	Day 13	41	97.1	97.0	1.39	94	100	41	-0.0	0.0	1.53	-4	3
	Day 14	39	97.6	98.0	1.09	95	100	39	0.4	0.0	1.07	-2	2
	Day 15	36	97.0	97.0	1.46	93	100	36	-0.1	0.0	1.56	-4	2
	Day 16	39	96.9	97.0	1.86	92	100	39	-0.3	0.0	1.99	-7	2
	Day 17	38	97.1	97.0	1.22	94	99	38	-0.2	0.0	1.56	-4	2
	Day 18	37	97.3	98.0	1.53	93	100	37	0.1	1.0	1.65	-5	2
	Day 19	39	97.2	98.0	1.90	91	100	39	0.0	1.0	1.80	-4	3
	Day 20	39	97.2	98.0	1.79	92	99	39	-0.1	1.0	1.86	-4	3
	Day 21	37	97.1	97.0	1.69	93	100	37	-0.2	0.0	1.97	-7	2

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Oxygen Saturation (%)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Day 22	37	97.1	97.0	1.68	94	100	37	-0.2	0.0	1.88	-5	3
	Day 23	37	97.3	98.0	1.66	93	100	37	-0.0	0.0	2.03	-7	2
	Day 24	35	97.5	98.0	1.25	95	100	35	0.0	0.0	1.50	-5	2
	Day 25	36	97.7	98.0	1.15	94	99	36	0.3	1.0	1.61	-4	3
	Day 26	32	97.5	98.0	1.37	94	100	32	0.1	1.0	1.68	-4	2
	Day 27	35	97.7	98.0	1.32	94	100	35	0.3	1.0	1.90	-5	3
	Day 28	37	97.5	98.0	1.59	92	100	37	0.1	1.0	1.87	-4	3
Placebo	Screening/Day -4 to -1	43	97.1	97.0	1.43	94	100						
	Day 1	40	97.1	97.0	1.32	94	99	0
	Day 2	43	96.6	97.0	1.83	91	99	42	-0.6	0.0	1.98	-7	2
	Day 3	43	96.6	97.0	2.03	90	99	43	-0.5	0.0	2.05	-7	2
	Day 4	42	96.9	98.0	2.28	86	99	42	-0.4	0.0	2.34	-12	2
	Day 5	42	96.6	97.9	2.98	86	100	42	-0.5	0.0	2.81	-12	3
	Day 6	41	97.3	98.0	1.68	92	99	41	0.0	0.0	1.60	-4	2
	Day 7	42	97.2	98.0	1.75	91	99	42	-0.0	1.0	2.08	-7	2

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Oxygen Saturation (%)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Placebo	Day 8	42	97.5	98.0	1.40	93	100	42	0.2	1.0	1.61	-4	3
	Day 9	41	97.1	98.0	1.86	90	99	41	-0.0	1.0	2.04	-8	3
	Day 10	40	97.5	98.0	1.38	94	99	40	0.3	0.5	1.88	-4	5
	Day 11	40	97.3	98.0	1.72	91	100	40	0.0	0.0	2.03	-5	4
	Day 12	40	97.5	98.0	1.85	90	100	40	0.2	1.0	1.94	-6	3
	Day 13	41	97.2	97.0	1.65	92	100	41	0.1	1.0	1.79	-6	3
	Day 14	42	97.7	98.0	1.33	94	100	42	0.6	0.0	1.71	-4	6
	Day 15	39	97.2	98.0	1.51	93	100	39	0.1	0.0	1.59	-4	3
	Day 16	42	97.4	98.0	1.64	91	100	42	0.3	1.0	1.81	-7	3
	Day 17	40	97.5	98.0	1.92	90	100	40	0.3	1.0	1.86	-6	3
	Day 18	39	97.2	98.0	1.90	91	100	39	0.1	1.0	2.13	-7	3
	Day 19	39	97.2	98.0	1.79	91	100	39	-0.1	1.0	2.09	-5	3
	Day 20	37	97.5	98.0	1.68	91	100	37	0.2	1.0	2.11	-7	3
	Day 21	35	97.7	98.0	1.30	94	100	35	0.4	1.0	1.48	-4	3
	Day 22	36	97.9	98.0	1.17	94	100	36	0.6	1.0	1.29	-2	3

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Oxygen Saturation (%)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Placebo	Day 23	39	97.6	98.0	1.41	92	100	39	0.4	1.0	1.59	-6	3
	Day 24	38	97.4	98.0	1.53	91	100	38	0.2	1.0	2.02	-7	3
	Day 25	35	97.7	98.0	1.24	94	100	35	0.5	1.0	1.56	-5	3
	Day 26	37	97.6	98.0	1.26	93	100	37	0.3	1.0	1.65	-5	3
	Day 27	37	97.5	98.0	1.35	92	99	37	0.3	1.0	1.65	-6	2
	Day 28	38	97.6	98.0	1.38	92	100	38	0.4	1.0	1.63	-6	3

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter:Weight (kg)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Screening/Day -4 to -1	43	82.6	81.1	20.17	48	145						
Placebo	Screening/Day -4 to -1	43	84.4	83.9	17.30	55	138						

COVID-19 AA
Protocol: 043

Table 14.1.9 Summary of Changes in Vital Signs from Baseline to Final Visit (Safety Population)

Parameter: Height (cm)

Treatment	Visit	n	Observed					n	Change from baseline				
			Mean	Median	SD	Min	Max		Mean	Median	SD	Min	Max
Tafenoquine	Screening/Day -4 to -1	43	166.2	165.1	10.84	140	188						
Placebo	Screening/Day -4 to -1	43	168.7	168.0	10.46	152	188						